Clinical Trials Arena34m
AD/PD 2025: Long-term data shows Anavex’s Blarcamesine benefits in early Alzheimer’s
Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.
Clinical Trials Arena1h
AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator
If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.
Clinical Trials Arena1h
Rhythm seeks market expansion for Imcivree following Phase III victory
Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...
Clinical Trials Arena3h
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial
Sonnet BioTherapeutics has reported positive safety outcomes from a trial of SON-1010 with atezolizumab for solid tumours or ...
Clinical Trials Arena6h
J&J’s psoriatic arthritis therapy trial meets endpoints
Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...
Clinical Trials Arena8h
CIRM awards $8m to Tr1X for trial of GvHD prevention drug candidate TRX103
The California Institute for Regenerative Medicine (CIRM) has given $8m to biotechnology company Tr1X to support its trial of ...
Clinical Trials Arena7h
Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.